Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Work In Process: 2022-2025

Historic Work In Process for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $4.7 million.

  • Arcutis Biotherapeutics' Work In Process rose 165.15% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 165.15%. This contributed to the annual value of $584,000 for FY2024, which is 20.16% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Work In Process stood at $4.7 million for Q3 2025, which was up 172.33% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Work In Process peaked at $4.7 million during Q3 2025, and registered a low of $116,000 during Q3 2022.
  • Over the past 3 years, Arcutis Biotherapeutics' median Work In Process value was $783,000 (recorded in 2025), while the average stood at $1.4 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Work In Process soared by 1,158.47% in 2024 and then tumbled by 66.00% in 2025.
  • Over the past 4 years, Arcutis Biotherapeutics' Work In Process (Quarterly) stood at $395,000 in 2022, then increased by 23.04% to $486,000 in 2023, then rose by 20.16% to $584,000 in 2024, then surged by 165.15% to $4.7 million in 2025.
  • Its Work In Process stands at $4.7 million for Q3 2025, versus $1.7 million for Q2 2025 and $783,000 for Q1 2025.